10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2022 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 17, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 6,933 | 7,071 | 4,495 |
| Adjustments to reconcile earnings to net cash from operating activities | |||
| Depreciation | 1,254 | 1,491 | 1,195 |
| Amortization of intangible assets | 2,013 | 2,047 | 2,132 |
| Investing and financing losses, net | 215 | 55 | 425 |
| Share-based compensation | 685 | 640 | 546 |
| Trade receivables | (68) | (383) | (924) |
| Inventories | (1,413) | (456) | (493) |
| Prepaid expenses and other assets | (75) | (312) | (627) |
| Trade accounts payable and other liabilities | 420 | 1,288 | 1,766 |
| Income taxes | (383) | (908) | (614) |
| Net Cash From Operating Activities | 9,581 | 10,533 | 7,901 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,777) | (1,885) | (2,177) |
| Acquisitions of businesses and technologies, net of cash acquired | 0 | (187) | (42) |
| Proceeds from business dispositions | 48 | 134 | 58 |
| Purchases of investment securities | (185) | (173) | (83) |
| Proceeds from sales of investment securities | 152 | 77 | 10 |
| Other | 22 | 26 | 19 |
| Net Cash From (Used in) Investing Activities | (1,740) | (2,008) | (2,215) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt, net and other | 47 | (204) | 2 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 7 | 4 | 1,281 |
| Repayments of long-term debt and debt with maturities over 3 months | (753) | (48) | (1,333) |
| Purchases of common shares | (3,795) | (2,299) | (403) |
| Proceeds from stock options exercised | 167 | 255 | 245 |
| Dividends paid | (3,309) | (3,202) | (2,560) |
| Other | 0 | 0 | (11) |
| Net Cash From (Used in) Financing Activities | (7,636) | (5,494) | (2,779) |
| Effect of exchange rate changes on cash and cash equivalents | (122) | (70) | 71 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 83 | 2,961 | 2,978 |
| Cash and Cash Equivalents, Beginning of Year | 9,799 | 6,838 | |
| Cash and Cash Equivalents, End of Year | 9,882 | 9,799 | 6,838 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,864 | 1,941 | 970 |
| Interest paid | 563 | 544 | 549 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |